19/11/2026
|

Why the smartest MedTech companies don't try to do everything themselves.

Your development pipeline is growing. Your headcount isn't. And the pressure to deliver is only increasing.

Do you recruit more engineers? Reprioritise your development pipeline? Delay your next product launch? Or bring in external expertise?

For many MedTech leaders, outsourcing product development is still seen as a tactical response to a shortage of internal resources.

But what if it was part of your innovation strategy rather than your contingency plan?

The real value of external development expertise isn't necessarily having more people working on a problem. It's having the right people, with the right experience, working on the right problem at the right time.

1. When your internal team is capable but overloaded

Most established MedTech companies have talented internal development teams.

But those teams are rarely focused exclusively on innovation. They're also managing existing products, regulatory changes, manufacturing issues, customer requirements and competing development programmes.

Something inevitably has to give.

And it's often the next generation of products.

A promising concept sits untouched. A development milestone slips. An opportunity to enter a new market is postponed.

Individually, these delays might appear manageable. Collectively, they can weaken a company's competitive position.

How many opportunities in your development pipeline are being delayed because of internal capacity rather than their commercial potential?

Bringing in a dedicated external team can allow important programmes to progress without compromising existing commitments or increasing permanent headcount.

2. When you need fresh thinking, not more of the same

Experience is one of the greatest strengths of an established development team.

It can also be one of its limitations.

Existing product architectures, familiar technologies, established suppliers and historical decisions can all influence how a new challenge is approached.

Sometimes the next generation of a medical device becomes an evolution of the existing product, when what is really needed is a fundamental rethink.

If you were designing your flagship medical device from scratch today, would you design it in the same way?

An independent development team can bring experience from different technologies, clinical applications and product categories.

It can challenge the original brief, question established assumptions and explore alternative approaches without being tied to historical decisions.

The value isn't simply additional engineering capacity. It's a different perspective on what might be possible.

3. When you have a problem, but not yet a solution

Not every development opportunity arrives with a clearly defined specification.

Perhaps you have identified an unmet clinical need.

Perhaps an emerging technology could transform an existing product category.

Perhaps customer feedback suggests your current device needs more than an incremental improvement.

You know there is an opportunity, but you don't yet know what the product should look like.

These are often the most interesting development challenges, but also the most difficult to accommodate within structured internal development programmes.

Does your organisation have the capacity and freedom to explore an opportunity before it can justify a fully funded development programme?

A small, experienced multidisciplinary team can explore concepts, build functional prototypes, test assumptions and establish whether an opportunity warrants further investment.

The objective is not to produce another innovation presentation.

It's to put something tangible on the table that enables your leadership team to make a better decision.

4. When time to market matters more than expanding headcount

Recruiting specialist expertise takes time.

Building a multidisciplinary team takes longer.

And once that team is established, the business carries the associated overhead regardless of how its development requirements change.

For organisations with fluctuating development pipelines, this can be an inefficient use of resources.

But the cost of a delayed launch can extend far beyond the development budget.

Lost revenue. Delayed market entry. Missed procurement opportunities. Competitive disadvantage.

When evaluating the cost of external development, are you comparing day rates or the commercial cost of delay?

The distinction matters.

An experienced external team that can mobilise quickly, work independently and deliver against clearly defined milestones may offer greater commercial value than a seemingly less expensive internal alternative.

The objective should be to optimise the return on development investment, not simply minimise the cost of engineering.

5. When specialist expertise can prevent expensive mistakes

Medical device development rarely presents a purely engineering challenge.

It requires the integration of industrial design, mechanical engineering, electronics, software, human factors, manufacturing and regulatory considerations.

A decision made in one discipline can have significant consequences elsewhere.

A technically successful sensor may be difficult to integrate into a wearable.

A sophisticated interface may introduce unnecessary use-related risks.

An innovative product architecture may be prohibitively expensive to manufacture.

The FDA's human factors guidance, ISO 14971 and IEC 62366-1 all reinforce the importance of addressing risk and usability throughout the development process.

Bringing in specialist expertise early can help identify problems before they become embedded in the design.

Which decisions in your current development programme would benefit from an independent assessment before you commit further resources?

Sometimes the greatest return on external expertise comes from avoiding work that should never have been undertaken in the first place.

6. Outsourcing doesn't mean outsourcing control

One of the understandable concerns for MedTech leaders is losing control of product development.

Intellectual property, technical knowledge, regulatory responsibilities and strategic product decisions are all important considerations.

But effective outsourcing doesn't require an organisation to surrender ownership of its innovation.

The relationship should be built around clear responsibilities, transparent communication, agreed deliverables, intellectual property arrangements and integration with the client's quality management processes.

Under the EU Medical Device Regulation and the FDA's quality management framework, outsourcing activities does not remove the manufacturer's applicable regulatory responsibilities.

The strongest external development relationships are collaborative.

The client retains strategic direction and ownership, subject to agreed contractual terms. The external team brings specialist expertise, independent thinking and focused execution.

Are you looking for a supplier to complete a task, or a development partner who understands what you're trying to achieve?

There is a significant difference.

7. When shouldn't you outsource?

External development expertise is not the answer to every challenge.

Where capabilities are central to long-term competitive differentiation, required continuously or fundamental to maintaining proprietary technical knowledge, building and retaining internal expertise may be the better approach.

Outsourcing should complement internal capabilities rather than create unnecessary dependency.

For many MedTech companies, the most effective model is a strong core internal team supported by flexible external expertise.

The question is not whether internal or external development is better.

It's how to combine the two to achieve the best commercial outcomes.

Five signs it's time to bring in external expertise

Think about your current development pipeline.

  • Important development programmes are repeatedly being delayed.
  • Your internal team is spending more time supporting existing products than developing new ones.
  • A promising technology needs to be translated into a commercially viable product.
  • You need specialist expertise that doesn't justify a permanent appointment.
  • Existing development approaches are failing to resolve a fundamental product challenge.

If several of these sound familiar, the issue may not be the quality of your internal team.

It may be how you're deploying your development resources.

Extend your capabilities, not your overheads

At Maddison, we've spent more than 40 years helping companies tackle complex product development challenges.

We're a small, highly experienced team of designers and engineers who work directly alongside internal development teams, bringing fresh thinking, specialist expertise and focused resources when they're needed most.

We can take an undefined problem, explore alternative solutions, build and test concepts, or help accelerate an existing programme towards commercial readiness.

Our senior-led approach means fewer layers of management, direct access to experienced specialists and a focus on practical outcomes.

Not more meetings.

Not more management.

Better products and better development decisions.

Because the smartest MedTech companies aren't necessarily those with the largest development teams.

They're the ones that know how to access the right expertise at the right time.

One final question

If your internal development team had unlimited capacity tomorrow, which opportunity would you pursue first?

And what's the commercial cost of not pursuing it today?

Perhaps it's time to have a different conversation about outsourcing.

Maddison. Design That Means Business.

References and further reading

  1. Chesbrough HW. Open Innovation: The New Imperative for Creating and Profiting from Technology. Harvard Business School Press, 2003. Explores how organisations can leverage external expertise and knowledge to support innovation.
  2. McKinsey & Company. The Business Value of Design, 2018. Research examining the relationship between design capabilities and commercial performance.
    https://www.mckinsey.com/capabilities/mckinsey-design/our-insights/the-business-value-of-design
  3. FDA. Applying Human Factors and Usability Engineering to Medical Devices, 2016.
    https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applying-human-factors-and-usability-engineering-medical-devices
  4. ISO 14971:2019. Medical devices: Application of risk management to medical devices.
  5. IEC 62366-1:2015+A1:2020. Medical devices: Application of usability engineering to medical devices.
  6. ISO 13485:2016. Medical devices: Quality management systems.
  7. FDA. Quality Management System Regulation (QMSR).
    https://www.fda.gov/medical-devices/postmarket-requirements-devices/quality-management-system-regulation-qmsr
  8. European Union. Regulation (EU) 2017/745 on medical devices.
    https://eur-lex.europa.eu/eli/reg/2017/745/oj